Limited Liability Company (LLC)
Simplement
Simplement Spółka z Ograniczoną Odpowiedzialnością
Limited Liability Company (LLC)
Simplement Spółka z Ograniczoną Odpowiedzialnością
Simplement Spółka z Ograniczoną Odpowiedzialnością (KRS 0000236444, NIP 1181800146) is a Polish company, headquartered in Janów, Mazowieckie voivodeship. Simplement operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since June 20, 2005. Simplement's most recently reported net revenue was 0 PLN for 2024.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Credibility rating
61 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
5
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/21 yrs
Board changes
0
0/21 yrs
PKD changes
2
2/21 yrs
Name changes
1
1/21 yrs
Data from 21 years of registry activity.
Payment reliability score from 2019–2024
Current: C (61/100)
Trend: improving (+3.7 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Standard limit from 2019–2024
Current: 9.7 K PLN
Safe: 4.4 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Founded
June 20, 2005
21 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
JANÓW
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
50.0 K PLN
100 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
5 years
2019–2024 · profitable: 0/5
Registry entries
41
latest: July 15, 2026
Revenue
0 PLN
2024
Net profit
0 PLN
2024
Assets
69.5 K PLN
2024
Equity
53.0 K PLN
2024
EBITDA
0 PLN
2024
Valuation
39.0 K PLN
Low confidence
Low confidence
People holding roles at Simplement according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
Rate business credibility - Simplement.
No ratings

Explainer
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.

Explainer
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
Simplement has 1 shareholder.
Yes - Simplement's majority owner is W**** K****.
Simplement's board has 1 member.
Latest reporting year
2025
Available years
19
Filing entries
0
Competing companies or those operating in the same market segment as Simplement (industry: Research and development).
WARSZAWA· Research and development
Revenue 2023: 420.1 K PLN
WARSZAWA· Research and development
Revenue 2024: 41.0 K PLN
JANÓW· Research and development
Revenue 2024: 0 PLN
WARSZAWA· Research and development
Revenue 2024: 0 PLN
WARSZAWA· Research and development
WARSZAWA· Research and development
Revenue 2020: 0 PLN
20 historical registry entries for Simplement
Filing documents submitted (3 documents)
Filing documents submitted (6 documents)
Filing documents submitted (3 documents)
Shareholder change
WA.XIV NS-REJ.KRS/23016/26/974
Filing documents submitted (3 documents)